Daily1d
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis
Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and ...
Zacks.com on MSN5d
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as ...
MyChesCo on MSN3d
Johnson & Johnson Advances Ulcerative Colitis Treatment with FDA Filing for TREMFYA® Subcutaneous Regimen
SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?
Goldman Sachs’ Scott Rubner predicts a year-end rally that will push the S&P to 6,200 points as reported by Bloomberg on ...
pharmaphorum5d
J&J plots filings after psoriasis drug clears phase 3 test
J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...
pharmaphorum5d
AAD: J&J’s oral IL-23 drug shows durability in psoriasis
such as J&J's own Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), and Sun Pharma’s Ilumya (tildrakizumab). FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg ...